Literature DB >> 8906993

Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection.

W Barcellini1, G P Rizzardi, G Poli, G Tambussi, C Velati, P L Meroni, A G Dalgleish, A Lazzarin.   

Abstract

We studied determinants of chronic inflammation and/or immune activation in plasma from patients in the transition from primary to early chronic HIV-1 infection. The following parameters were estimated in seven patients over time: plasma concentrations of soluble CD8 (sCD8), tumor necrosis factor alpha (TNF-alpha), soluble TNF receptor type II (sTNFRII), interleukin 6 (IL-6), soluble IL-6 receptor (sIL6R), IL-10, transforming growth factor beta1 (TGF-beta1), along with CD4- and CD8-positive T cell counts, p24 antigenemia, and clinical evaluation. Results showed that concentrations of sCD8, TNF-alpha, and sTNFRII, and peripheral CD8-positive lymphocyte counts, were significantly increased in patients, compared to HIV-negative controls, and showed a trend toward normal values over time. Levels of IL6, sIL6R, IL-10, and TGF-beta1 did not differ from those of controls and did not change over time. Heterogeneity was observed among the patients in terms of CD4-positive T cell depletion, levels of sCD8, concentrations of TNF-alpha/sTNFRII, and clinical outcome. These data indicate that in the transition phase from primary acute to chronic and asymptomatic infection the host immune activation in response to the virus is highly heterogeneous and that the sustained rise in TNF-alpha and its receptor may represent an important therapeutic target in early disease. The persistence of a state of chronic inflammation and/or immune activation could influence the progression of disease independently from CD4-positive T cell counts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906993     DOI: 10.1089/aid.1996.12.325

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Authors:  Adriana A Byrnes; David M Harris; Sowsan F Atabani; Beulah P Sabundayo; Susan J Langan; Joseph B Margolick; Christopher L Karp
Journal:  J Leukoc Biol       Date:  2008-09-19       Impact factor: 4.962

2.  Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients.

Authors:  G Hittinger; C Poggi; E Delbeke; N Profizi; A Lafeuillade
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

Review 3.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

Review 4.  Mucosal immunity in human and simian immunodeficiency lentivirus infections.

Authors:  J M Brenchley
Journal:  Mucosal Immunol       Date:  2013-04-03       Impact factor: 7.313

5.  Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection.

Authors:  Philip J Norris; Brandee L Pappalardo; Brian Custer; Gerald Spotts; Frederick M Hecht; Michael P Busch
Journal:  AIDS Res Hum Retroviruses       Date:  2006-08       Impact factor: 2.205

6.  The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women.

Authors:  Sheila M Keating; Elizabeth T Golub; Marek Nowicki; Mary Young; Kathryn Anastos; Howard Crystal; Mardge H Cohen; Jinbing Zhang; Ruth M Greenblatt; Seema Desai; Shiquan Wu; Alan L Landay; Stephen J Gange; Philip J Norris
Journal:  AIDS       Date:  2011-09-24       Impact factor: 4.177

Review 7.  Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Authors:  Sheila M Keating; Evan S Jacobs; Philip J Norris
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

8.  Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Authors:  Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

9.  Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation.

Authors:  Clarisa M Buckner; Susan Moir; Jason Ho; Wei Wang; Jacqueline G Posada; Lela Kardava; Emily K Funk; Amy K Nelson; Yuxing Li; Tae-Wook Chun; Anthony S Fauci
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

10.  Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type response.

Authors:  G P Rizzardi; J B Marriott; S Cookson; A Lazzarin; A G Dalgleish; W Barcellini
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.